These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36791331)

  • 1. Competition And Vulnerabilities In The Global Supply Chain For US Generic Active Pharmaceutical Ingredients.
    Socal MP; Ahn K; Greene JA; Anderson GF
    Health Aff (Millwood); 2023 Mar; 42(3):407-415. PubMed ID: 36791331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolution of Supply and Demand in Markets for Generic Drugs.
    Frank RG; McGuire TG; Nason I
    Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.
    Fortunak JM; de Souza RO; Kulkarni AA; King CL; Ellison T; Miranda LS
    Antivir Ther; 2014; 19 Suppl 3(0 3):15-29. PubMed ID: 25310430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of COVID-19 on the global supply chain of antiretroviral drugs: a rapid survey of Indian manufacturers.
    Rewari BB; Mangadan-Konath N; Sharma M
    WHO South East Asia J Public Health; 2020 Sep; 9(2):126-133. PubMed ID: 32978345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world?
    Guerin PJ; Singh-Phulgenda S; Strub-Wourgaft N
    F1000Res; 2020; 9():225. PubMed ID: 32566139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on the Benefits of US Pharmacopeial Standards: A Generic Pharmaceutical Industry Survey.
    Warthin IK; Berik J; Podolsky D; Raghavendran V; Reddy R; Chang J; Porter N; Garito N
    J Pharm Sci; 2020 Feb; 109(2):944-949. PubMed ID: 31606539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The production and exportation of artemisinin-derived drugs in China: current status and existing challenges.
    Huang Y; Li H; Peng D; Wang Y; Ren Q; Guo Y
    Malar J; 2016 Jul; 15():365. PubMed ID: 27421885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US Generic Antiseizure Medication Supply Chain: Observations from Analysis of US Government Databases.
    Javarayee P; Meylor J; Shahrukh S; Pollock S; Andrade-Machado R; Sah J; Patel H
    Seizure; 2024 Apr; 117():83-89. PubMed ID: 38354597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Shortages of Prescription Drugs Due to Compliance and Quality Issues in Japan].
    Izutsu KI; Abe Y; Kurita M; Yoshida H
    Yakugaku Zasshi; 2023 Feb; 143(2):139-152. PubMed ID: 36418079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating The Effects Of COVID-19 On Globalized Markets For Active Pharmaceutical Ingredients.
    Barber M; Ramachandran R; Moon S
    Health Aff (Millwood); 2024 Jul; 43(7):959-969. PubMed ID: 38950300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Countries Manufacturing Pharmaceuticals for the US Market: A 10-Year Analysis of Public Data.
    Hatton RC; Leighton G; Englander L
    Ann Pharmacother; 2022 Oct; 56(10):1106-1112. PubMed ID: 35040353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global Production of Active Pharmaceutical Ingredients for US Generic Drugs Experiencing Shortages.
    Socal MP; Crane MA; Anderson GF
    JAMA; 2024 May; 331(20):1763-1765. PubMed ID: 38683587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.
    Petrelli F; Caraffa A; Scuri S; Grappasonni I; Magrini E; Cocchini A
    Acta Biomed; 2019 May; 90(2):288-299. PubMed ID: 31125009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perceived impact of the patent linkage system on pharmaceutical market from the viewpoint of the domestic manufacturers in South Korea.
    Choi N; Son KB; Byun J; Yang DW
    Global Health; 2022 Mar; 18(1):34. PubMed ID: 35313916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market.
    Nakakeeto ON; Elliott BV
    Global Health; 2013 Feb; 9():6. PubMed ID: 23410145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased topical generic prices by manufacturers.
    Bhatt MD; Bhatt BD; Dorrian JT; McLellan BN
    J Am Acad Dermatol; 2019 May; 80(5):1353-1357. PubMed ID: 29544742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceuticals imports in Tanzania: Overview of private sector market size, share, growth and projected trends to 2021.
    Wande DP; Sangeda RZ; Tibalinda P; Mutta IK; Mkumbwa S; Bitegeko A; Kaale E
    PLoS One; 2019; 14(8):e0220701. PubMed ID: 31404109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
    Babovic S; Wasan KM
    J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coping with drug shortages: A study of government-enterprise option cooperation stockpiling strategies for drugs in shortage considering API surrogate stockpiling subsidies.
    Lan Y; Meng C; Sun L; Huang Z
    PLoS One; 2024; 19(7):e0305383. PubMed ID: 38954737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.